


Hetero introduces HumiraTM to treat rheumatoid arthritis in India

03 January 2018 | News

The product will be marketed by Hetero Healthcare under the brand name 'MaburaTM' in India



Hetero is one of India's leading generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs for the treatment of HIV/AIDS.

The company has launched its fourth biosimilar drug 'Adalimumab' under the brand name 'MaburaTM' in India.

Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.

Indian drug maker Hetero has launched a biosimilar of AbbVie's 'HumiraTM' (adalimumab) for the treatment of rheumatoid arthritis and other auto immune disorders in India.

MaburaTM is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF) and the auto-immune disorders it is indicated for include psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.

According to company, the product will be marketed by Hetero Healthcare under the brand name 'MaburaTM' in India.

MaburaTM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously.

Hetero did not disclose the price at which it would be marketing the drug in the country.